MaxCyte, Inc. Total Voting Rights (6888C)
24 January 2018 - 12:32AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 6888C
MaxCyte, Inc.
23 January 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Maryland, USA - 23 January 2018: MaxCyte (LSE: MXCT, MXCR)
announces that, following an exercise of options, 18,293 new shares
of common stock of $0.01 each in the Company (the "Common Stock")
were issued from the blocklisting facility granted 5 May 2017.
The total issued stock capital of the Company has consequently
increased to 50,914,669, Common Stock. There is no Common Stock
held in treasury. Therefore, the total number of voting rights in
the Company is 50,914,669. Stockholders in the Company may use this
figure as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 35,401,561 and the number of restricted shares
of Common Stock trading under the symbol 'MXCR' is 15,513,108. The
number of Common Stock capable of being issued under the
blocklisting facility is 899,858 Common Stock.
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering products and services to
biopharmaceutical firms engaged in cell therapy, drug discovery and
development, biomanufacturing, gene editing and immuno-oncology
markets, which independent market analyses estimate to be, in
aggregate, in excess of $35 billion in 2015. The Company's patented
flow electroporation technology enables its products to deliver
fast, reliable and scalable cell engineering to drive the research
and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, clinical and
commercial grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is
developing CARMA, its proprietary platform in immuno-oncology, to
deliver a validated non-viral approach to CAR therapies across a
broad range of cancer indications, including solid tumors where
existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRFKNDNNBKDDDB
(END) Dow Jones Newswires
January 23, 2018 08:32 ET (13:32 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024